ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2009
Detection of galectin-3 in patients with inflammatory bowel diseases: new serum marker of active forms of IBD?
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 55 citations in OpenAlex.
- Diagnostic Potential of Periostin, Galectin-3 and Tenascin C Serum Measurements in Inflammatory Bowel Disease: Pilot Study.International journal of molecular sciences · 2025Article
- Review
- Galectin-3-Insights from Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.International journal of molecular sciences · 2025Review
- Ligands for Intestinal Intraepithelial T Lymphocytes in Health and Disease.Pathogens (Basel, Switzerland) · 2025Review
- The effect of rs2910686 on ERAP2 expression in IBD and epithelial inflammatory response.Journal of translational medicine · 2024Article
- Serum Galectin-3 as a Non-Invasive Marker for Primary Sclerosing Cholangitis.International journal of molecular sciences · 2024Article
- Balancing Act of the Intestinal Antimicrobial Proteins on Gut Microbiota and Health.Journal of microbiology (Seoul, Korea) · 2024Review
- Proteolytic processing of galectin-3 by meprin metalloproteases is crucial for host-microbiome homeostasis.Science advances · 2023Article
- Soluble IgE-binding factors in the serum of food-allergic patients: Possible pathophysiological role of soluble FcεRI as protective factor.Clinical and translational allergy · 2023Article
- Highlights on the Role of Galectin-3 in Colorectal Cancer and the Preventive/Therapeutic Potential of Food-Derived Inhibitors.Cancers · 2022Review
- Antimicrobial peptides and the gut microbiome in inflammatory bowel disease.World journal of gastroenterology · 2021Article
- A Pilot Clinical Study on Post-Operative Recurrence Provides Biological Clues for a Role ofJournal of fungi (Basel, Switzerland) · 2021Article
- The Role of Glycosylation in Inflammatory Diseases.Advances in experimental medicine and biology · 2021Article
- Article
- Serum Biomarkers for Inflammatory Bowel Disease.Frontiers in medicine · 2020Review
- Metabolic syndrome attenuates ulcerative colitis: Correlation with interleukin-10 and galectin-3 expression.World journal of gastroenterology · 2019Article
- Article
- Activation of Resolution Pathways to Prevent and Fight Chronic Inflammation: Lessons From Asthma and Inflammatory Bowel Disease.Frontiers in immunology · 2019Review
- Damage-associated molecular patterns in inflammatory bowel disease: From biomarkers to therapeutic targets.World journal of gastroenterology · 2018Review
- Review of autoinflammatory diseases, with a special focus on periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome.Acta paediatrica (Oslo, Norway : 1992) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIt is an open question whether multifunctional galectin-3 can be a serum marker in inflammatory bowel disease.
methodsWestern blots and commercial ELISA detected and quantitated the lectin immunocytochemistry using double labeling localized it in tissue sections.
resultsSerum concentrations were significantly increased in specimen of patients with active and remission-stage ulcerative colitis and Crohn's disease, associated with emerging positivity of CD14(+) cells.
conclusionEnhanced concentration of galectin-3 in serum reflects presence of disease and points to its involvement in the pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.